$XBI $114.57 +2.18%
Covid Updates
$VALN +0.62% Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001 source
Pipeline Updates
$PTGX +5.7% Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications source
$ZGNX +2.6% Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021 source
$DYN -1.6% Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy source
$DCTH -6.0% Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis source
$MRUS +3.4% Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021 source
$ONTX +5.5% Onconova Therapeutics Announces The Presentation Of Preliminary Clinical Data Providing Evidence Of Rigosertib’s Activity In RDEB-Associated Squamous Cell Carcinoma source
$OMER +7.3% OMEROS ANNOUNCES AGREEMENT TO SELL OMIDRIA® FRANCHISE TO RAYNER SURGICAL IN A TRANSACTION VALUED IN EXCESS OF $1 BILLION source
$RDHL +0.7% RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI source
$SURF +1.1% Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 source
$KPTI +8.8% Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer source
$EPZM +6.0% Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting source
$SQZ -4.8% SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose source
$BOLT +4.8% Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021 December 2, 2021 source
Business Updates
$ESPR +11.6% Esperion Announces Proposed Public Offering source
Posted by JM
Comments